Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
April 03, 2023 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
March 16, 2023 08:31 ET
|
Shattuck Labs, Inc.
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease – AUSTIN,...
Shattuck Labs Announces Participation in Upcoming March Conferences
March 01, 2023 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
February 23, 2023 16:30 ET
|
Shattuck Labs, Inc.
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with...
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
February 16, 2023 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
February 09, 2023 06:01 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
January 09, 2023 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 08, 2022 16:30 ET
|
Shattuck Labs, Inc.
– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in...
Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2022 08:00 ET
|
Shattuck Labs, Inc.
- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the...
Shattuck Labs Announces Participation in Upcoming November Conferences
November 03, 2022 08:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...